Bayer joins Sensyne Health consortium

Bayer has joined the Sensyne Health consortium working on national linked patient data capability for accelerating the discovery of new medicines.

Bayer joins Microsoft, EY, JP Morgan, and Peel Hunt in the consortium to become Sensyne Health’s preferred pharmaceutical partner.

Under the terms of this new Memorandum of Understanding Bayer will work with Sensyne Health and the consortium members as they develop proposals to scale Sensyne Health’s current network of strategic research agreements with NHS Trusts.  The purpose of this network is to accelerate the discovery and development of new medicines and improve patient care through the analysis of large databases of anonymised patient data, using clinical artificial intelligence. Bayer will provide Sensyne Health with strategic insight and advice regarding the research, development and commercialisation of new medicines, medical devices and biomarkers to aid the design of these proposals.

Sensyne Health acts as a ‘docking station’ for the analysis of anonymised patient data on behalf of its commercial partners under strict ethical controls.

Kemal Malik MD, Bayer board member for Innovation, said  “Access to anonymised national linked patient data heralds a new era in the discovery and development of medicines.  Through the application of artificial intelligence to large sets of patient information it becomes possible to identify people that are most likely to be at risk of diseases in the future.  Importantly, this will allow steps to prevent their progress along that path.  Bayer is excited to make its expertise available to develop this capability.”

Lord (Paul) Drayson, Chief Executive Officer of Sensyne Health plc, said “I am delighted to have agreed this partnership with Bayer. Sensyne Health’s consortium of experts already benefits from a vast array of expertise, and bringing Bayer to the table, with its long history of drug discovery and in depth pharmaceutical knowledge, will increase the chances of developing new medicines and ultimately help to relieve the strain on the NHS. Clinical AI has enormous potential for the UK health sector and Sensyne Health, along with its partners, is proud to be at the forefront of efforts to leverage this important technology in the U.K. for the benefit of patients, clinicians and the country as a whole.”